• Kairos Pharma posted a Q2 net loss of USD 1.39 million, narrowing from USD 1.42 million a year earlier.
• Operating loss improved to USD 1.42 million as total operating expenses edged down to USD 1.42 million.
• Research and development spending rose to USD 619,000, driven by a Phase 2 prostate cancer trial that began in 2024.
• General and administrative costs fell to USD 798,000; interest income slipped to USD 29,000.
• Cash and short-term investments totaled USD 2.63 million at June 30; the company flagged substantial doubt about going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037355), on August 12, 2026, and is solely responsible for the information contained therein.